Analysts Offer Predictions for Moderna FY2026 Earnings

Moderna, Inc. (NASDAQ:MRNA) – Brookline Capital Management decreased their FY2026 earnings per share (EPS) estimates for shares of Moderna in a report released on Wednesday, October 22nd. Brookline Capital Management analyst L. Cann now anticipates that the company will post earnings per share of ($0.32) for the year, down from their previous forecast of ($0.16). The consensus estimate for Moderna’s current full-year earnings is ($9.61) per share. Brookline Capital Management also issued estimates for Moderna’s FY2027 earnings at $3.36 EPS, FY2028 earnings at $5.33 EPS and FY2029 earnings at $19.41 EPS.

Other research analysts also recently issued reports about the stock. Citigroup cut their price target on shares of Moderna from $30.00 to $28.00 and set a “neutral” rating for the company in a report on Thursday, October 23rd. Morgan Stanley increased their price objective on Moderna from $31.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Friday, October 10th. Evercore ISI set a $32.00 target price on Moderna in a research report on Friday, August 1st. Wells Fargo & Company restated an “equal weight” rating on shares of Moderna in a research note on Sunday, July 13th. Finally, Leerink Partners dropped their price target on Moderna from $18.00 to $15.00 and set an “underperform” rating for the company in a research report on Friday, August 22nd. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, twelve have given a Hold rating and five have assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $36.86.

Moderna Trading Down 0.3%

Moderna stock opened at $26.66 on Monday. Moderna has a 1-year low of $23.15 and a 1-year high of $57.69. The firm has a market capitalization of $10.41 billion, a PE ratio of -3.54 and a beta of 2.01. The firm’s 50 day simple moving average is $25.91 and its 200 day simple moving average is $27.15.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Friday, August 1st. The company reported ($2.13) earnings per share for the quarter, beating the consensus estimate of ($2.99) by $0.86. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.The firm had revenue of $142.00 million for the quarter, compared to analysts’ expectations of $116.26 million. During the same period in the prior year, the business posted ($3.33) earnings per share. The company’s revenue was down 41.1% on a year-over-year basis. Moderna has set its FY 2025 guidance at EPS.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of MRNA. Bayforest Capital Ltd purchased a new position in shares of Moderna during the third quarter worth approximately $392,000. Oregon Public Employees Retirement Fund grew its holdings in shares of Moderna by 34.5% during the 3rd quarter. Oregon Public Employees Retirement Fund now owns 39,548 shares of the company’s stock valued at $1,022,000 after purchasing an additional 10,137 shares during the last quarter. Nisa Investment Advisors LLC raised its position in Moderna by 50.0% in the 3rd quarter. Nisa Investment Advisors LLC now owns 16,246 shares of the company’s stock worth $420,000 after purchasing an additional 5,417 shares during the period. HB Wealth Management LLC raised its position in Moderna by 50.2% in the 3rd quarter. HB Wealth Management LLC now owns 10,933 shares of the company’s stock worth $282,000 after purchasing an additional 3,652 shares during the period. Finally, CX Institutional lifted its stake in Moderna by 589.4% in the third quarter. CX Institutional now owns 7,121 shares of the company’s stock worth $184,000 after purchasing an additional 6,088 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.